Arshin Sheybani, MD
Radiation Oncology · Des Moines, IANPI 1407082712
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,000 of the $4,479 with a category attached, or 67.0%. Novartis accounts for 69.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $3,256 and has fallen 76.3% since, to $771 in 2025. Among radiation oncology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $135.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Siemens Medical Solutions USA, Inc.$419
- GT Medical Technologies, Inc$248
- Novocure Inc.$247
- Reflexion Medical, Inc.$156
- Pfizer$125
- plus $157 from 5 others
What the payments were for
- Consulting fees$3,00067%
- Travel & lodging$2636%
- Food & beverage$1,21627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $3,128 |
| Siemens Medical Solutions USA, Inc. | 7 | $419 |
| GT Medical Technologies, Inc | 2 | $248 |
| Novocure Inc. | 8 | $247 |
| Reflexion Medical, Inc. | 1 | $156 |
| Pfizer | 1 | $125 |
| Bayer | 3 | $74 |
| Tolmar Pharmaceuticals, Inc. | 2 | $32 |
| AstraZeneca | 1 | $23 |
| Boston Scientific | 1 | $16 |
| Palette Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,479 in reported general payments places this provider in the 95th percentile of 55 radiation oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $695 |
| Gabapentin | 26 | $622 |
| Betamethasone Valerate | 23 | $613 |
| Dexamethasone | 12 | $368 |
| Tamsulosin Hcl | 15 | $219 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Des Moines
- Dev PuriDes Moines$32K
- Robert IsaakDes Moines$3K
- Sarah McAvoyDes Moines$1K
- Richard DemingDes Moines$890
- Samuel SchroederDes Moines$876
- George VoynovDes Moines$865
- John TriantafyllosDes Moines$623
- John MartensDes Moines$476
- Philip ColletierDes Moines$438
- Truston BodineDes Moines$419
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.